Full Text View
Tabular View
No Study Results Posted
Related Studies
Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis
This study is ongoing, but not recruiting participants.
Study NCT01185821   Information provided by Novartis

First Received on August 19, 2010.   Last Updated on January 18, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Autoimmune Diseases
Immune System Diseases
Nervous System Diseases
Additional conditions recognized in this trial
Autoimmune Diseases of the Nervous System
Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Sclerosis
More general conditions related to this trial
Demyelinating Autoimmune Diseases, CNS
Demyelinating Diseases
Pathologic Processes
Interventions listed in this trial
BAF312
Sponsors listed in this trial
Novartis


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services